What question did this study set out to answer?

The study aimed to investigate the role of NAT10 as a therapeutic target in pulmonary fibrosis.

Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates that inhibiting NAT10 reduces lung damage in pulmonary fibrosis, suggesting a novel treatment approach.

The study aimed to investigate the role of NAT10 as a therapeutic target in pulmonary fibrosis.
Utilized small-molecule inhibitor Remodelin to block NAT10 activity in vivo and in vitro.
Analyzed lung tissues from IPF patients and bleomycin-treated mice to assess NAT10 expression.
Conducted rescue experiments to confirm the involvement of the C/EBPβ-ITGA11 axis.
NAT10 was significantly upregulated in IPF lung tissues and bleomycin-treated mice.
Inhibition of NAT10 with Remodelin reduced collagen deposition and lung destruction, p<0.05.
NAT10 was found to stabilize C/EBPβ mRNA, leading to increased ITGA11 expression and fibroblast activation.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark